FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1893972896> ?p ?o ?g. }

• W1893972896 abstract "The paper by Hartter et al. on the interaction between dabigatran etexilate and rifampicin [1] is an important addition to the published data on drug–drug interactions involving dabigatran etexilate. Dabigatran etexilate is a substrate of intestinal P-glycoprotein (P-gp). Compared with dabigatran etexilate alone, the co-administration of rifampicin, a P-gp inducer, was associated with a 67% reduction in dabigatran AUC(0,∞). Consequently, Hartter et al. recommend that this drug–drug interaction be managed by avoiding the combination of dabigatran etexilate and rifampicin or any other P-gp inducers, e.g. carbamazepine. We would like to suggest an alternative management strategy to avoidance of such drug combinations.The interaction with rifampicin or other P-gp inducers could be managed by laboratory coagulation monitoring and appropriate dose adjustment of dabigatran. As Hartter et al. point out, rifampicin also has a significant impact on warfarin concentrations. O'Reilly demonstrated a reduction in steady-state plasma warfarin concentrations of around 85% [2]. Instead of avoidance, the combination of rifampicin and warfarin is managed by monitoring the International Normalized Ratio (INR) and appropriate warfarin dose adjustment.It may not be immediately clear how laboratory coagulation monitoring should proceed, given that none of the phase III studies of dabigatran etexilate used targeted dosing based on coagulation assay values. However, published data show excellent correlation between dabigatran concentrations and various coagulation assays, e.g. Hemoclot® Thrombin Time (HTT, r2 = 0.99) [3]. Pharmacokinetic data from the RE-LY study of dabigatran etexilate for atrial fibrillation revealed plasma dabigatran concentrations of 50–300 μg l−1 [4]. Using these concentrations, target values for anticoagulation may be read off the correlation graphs, e.g. 40–75 s for HTT.Laboratory coagulation monitoring is also likely to be useful for other pharmacokinetic drug−drug interactions involving dabigatran. The European Union label for dabigatran etexilate currently includes a confusing list of dosing recommendations for various pharmacokinetic interactions [5]. For example, rifampicin is ‘not recommended’ because of a 67% reduction in concentrations, whereas the guidance for amiodarone, which is associated with a 60% increase in concentrations, is ‘use with caution and assess bleeding risk’ without any suggestion for dose adjustment. Further, how one should manage the co-administration of multiple drugs affecting dabigatran concentrations is unclear. Dose adjustment of dabigatran etexilate based on feedback from laboratory coagulation monitoring seems a reasonable answer to these concerns, and would allow more patients to benefit from this drug." @default.
• W1893972896 created "2016-06-24" @default.
• W1893972896 creator A5014662526 @default.
• W1893972896 creator A5034417886 @default.
• W1893972896 creator A5036705114 @default.
• W1893972896 date "2013-01-10" @default.
• W1893972896 modified "2023-09-27" @default.
• W1893972896 title "Rifampicin and dabigatran etexilate: a place for laboratory coagulation monitoring" @default.
• W1893972896 cites W1812338265 @default.
• W1893972896 cites W1997854923 @default.
• W1893972896 cites W2015957225 @default.
• W1893972896 cites W2113446992 @default.
• W1893972896 doi "https://doi.org/10.1111/j.1365-2125.2012.04408.x" @default.
• W1893972896 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3579270" @default.
• W1893972896 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23302069" @default.
• W1893972896 hasPublicationYear "2013" @default.
• W1893972896 type Work @default.
• W1893972896 sameAs 1893972896 @default.
• W1893972896 citedByCount "5" @default.
• W1893972896 countsByYear W18939728962013 @default.
• W1893972896 countsByYear W18939728962014 @default.
• W1893972896 countsByYear W18939728962015 @default.
• W1893972896 countsByYear W18939728962017 @default.
• W1893972896 countsByYear W18939728962018 @default.
• W1893972896 crossrefType "journal-article" @default.
• W1893972896 hasAuthorship W1893972896A5014662526 @default.
• W1893972896 hasAuthorship W1893972896A5034417886 @default.
• W1893972896 hasAuthorship W1893972896A5036705114 @default.
• W1893972896 hasBestOaLocation W18939728962 @default.
• W1893972896 hasConcept C112705442 @default.
• W1893972896 hasConcept C126322002 @default.
• W1893972896 hasConcept C142724271 @default.
• W1893972896 hasConcept C2776301958 @default.
• W1893972896 hasConcept C2776710957 @default.
• W1893972896 hasConcept C2778382381 @default.
• W1893972896 hasConcept C2778607973 @default.
• W1893972896 hasConcept C2778810321 @default.
• W1893972896 hasConcept C2779161974 @default.
• W1893972896 hasConcept C2780272996 @default.
• W1893972896 hasConcept C2781069245 @default.
• W1893972896 hasConcept C71924100 @default.
• W1893972896 hasConcept C97320921 @default.
• W1893972896 hasConcept C98274493 @default.
• W1893972896 hasConceptScore W1893972896C112705442 @default.
• W1893972896 hasConceptScore W1893972896C126322002 @default.
• W1893972896 hasConceptScore W1893972896C142724271 @default.
• W1893972896 hasConceptScore W1893972896C2776301958 @default.
• W1893972896 hasConceptScore W1893972896C2776710957 @default.
• W1893972896 hasConceptScore W1893972896C2778382381 @default.
• W1893972896 hasConceptScore W1893972896C2778607973 @default.
• W1893972896 hasConceptScore W1893972896C2778810321 @default.
• W1893972896 hasConceptScore W1893972896C2779161974 @default.
• W1893972896 hasConceptScore W1893972896C2780272996 @default.
• W1893972896 hasConceptScore W1893972896C2781069245 @default.
• W1893972896 hasConceptScore W1893972896C71924100 @default.
• W1893972896 hasConceptScore W1893972896C97320921 @default.
• W1893972896 hasConceptScore W1893972896C98274493 @default.
• W1893972896 hasLocation W18939728961 @default.
• W1893972896 hasLocation W18939728962 @default.
• W1893972896 hasLocation W18939728963 @default.
• W1893972896 hasLocation W18939728964 @default.
• W1893972896 hasOpenAccess W1893972896 @default.
• W1893972896 hasPrimaryLocation W18939728961 @default.
• W1893972896 hasRelatedWork W117746909 @default.
• W1893972896 hasRelatedWork W1926627776 @default.
• W1893972896 hasRelatedWork W1974273817 @default.
• W1893972896 hasRelatedWork W2001598988 @default.
• W1893972896 hasRelatedWork W2025511815 @default.
• W1893972896 hasRelatedWork W2026375542 @default.
• W1893972896 hasRelatedWork W2062946016 @default.
• W1893972896 hasRelatedWork W2089732951 @default.
• W1893972896 hasRelatedWork W2113446992 @default.
• W1893972896 hasRelatedWork W2168403443 @default.
• W1893972896 hasRelatedWork W2316021237 @default.
• W1893972896 hasRelatedWork W2324753864 @default.
• W1893972896 hasRelatedWork W2424459362 @default.
• W1893972896 hasRelatedWork W2461154326 @default.
• W1893972896 hasRelatedWork W2773019281 @default.
• W1893972896 hasRelatedWork W2884379119 @default.
• W1893972896 hasRelatedWork W2894214336 @default.
• W1893972896 hasRelatedWork W3140766786 @default.
• W1893972896 hasRelatedWork W166254307 @default.
• W1893972896 hasRelatedWork W2186846525 @default.
• W1893972896 isParatext "false" @default.
• W1893972896 isRetracted "false" @default.
• W1893972896 magId "1893972896" @default.
• W1893972896 workType "article" @default.